MedTrace Logo

Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.

NCT00739206 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2010-06-16

No results posted yet for this study

Summary

The objective of the study is to assess the efficacy and safety of SAR97276A in severe malaria in pediatric patients. Before treating pediatric patients with severe malaria, the efficacy and safety of SAR97276A will be first tested in adult patients, then in pediatric patients, with uncomplicated malaria.

The safety and the concentration of SAR97276A in blood and plasma will be assessed in adult and pediatric patients.

Conditions

Interventions

DRUG

SAR97276A

Dose based on body weight

Sponsors & Collaborators

Principal Investigators

  • ICD CSD · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Benin
  • Burkina Faso
  • Gabon
  • Tanzania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00739206 on ClinicalTrials.gov